Latest SION news and sentiment

Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sionna Therapeutics, Inc. (NASDAQ: SION) following a significant drop in its stock price. This comes after Sionna reported disappointing topline data from its PreciSION CF Phase 2a trial and announced it would not advance SION-719. The firm is encouraging shareholders who purchased Sionna securities to contact them to learn more about potential claims.

Robbins LLP Reminds Investors it is Investigating Sionna Therapeutics for Potential Securities Violations

Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) for potential securities violations and breaches of fiduciary duties after its stock plunged 92% following disappointing Phase 2a clinical trial results for SION-719 in cystic fibrosis. The trial failed to meet its primary endpoint, leading the company to consider capital preservation measures. Shareholders who lost money are encouraged to contact Robbins LLP for more information.

Securities Fraud Investigation Into Sionna Therapeutics,

The Law Offices of Frank R. Cruz is continuing its investigation into Sionna Therapeutics, Inc. (SION) regarding potential violations of federal securities laws after the company announced a primary endpoint miss in its PreciSION CF Phase 2a trial. This news led to a 91.2% stock drop, injuring investors. Shareholders who lost money are encouraged to contact the firm to potentially pursue a claim.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sionna Therapeutics, Inc. (SION) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sionna Therapeutics, Inc. (SION) following a significant drop in its stock price. This comes after Sionna reported a primary endpoint miss in its PreciSION CF Phase 2a trial and announced it would not advance SION-719. The law firm is encouraging investors who purchased Sionna securities to contact them to assist with the investigation into potential claims.

Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

Robbins Geller Rudman & Dowd LLP has launched an investigation into potential violations of U.S. federal securities laws by Sionna Therapeutics, Inc. (NASDAQ: SION). This follows an announcement by Sionna Therapeutics on August 10, 2026, that its SION-719 Phase 2a trial did not meet its key activity endpoint, causing a stock price drop of over 91%. The law firm is encouraging investors who suffered losses and potential witnesses to contact them for more information.

Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics

Robbins LLP, a shareholder rights law firm, is investigating Sionna Therapeutics (NASDAQ: SION) following a 92% stock drop. The investigation comes after the company reported disappointing results from its Phase 2a study of SION-719 for cystic fibrosis, failing to meet its key activity endpoint. Shareholders who have lost money investing in Sionna Therapeutics are encouraged to contact Robbins LLP for more information.

Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky, LLP has announced a securities investigation into Sionna Therapeutics (NASDAQ: SION) following a significant 92% drop in its share price. This decline occurred after the company revealed that its Phase 2a PreciSION CF trial for SION-719 failed to meet its primary endpoint, leading to the decision not to advance the candidate as an add-on therapy. The investigation will examine whether investors received adequate disclosure regarding the company's reliance on its NBD1 stabilizer programs and the associated risks.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sionna Therapeutics, Inc. (SION) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sionna Therapeutics, Inc. (SION) following a significant drop in its stock price. The investigation stems from Sionna's August 10, 2026, announcement of topline data from its PreciSION CF Phase 2a trial, which included a primary endpoint miss and the decision not to advance SION-719 as an add-on therapy. The firm encourages Sionna stockholders to join the investigation, which aims to recover investor capital.

Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP has initiated a securities fraud investigation into Sionna Therapeutics, Inc. (SION) following a significant stock drop. The investigation comes after Sionna announced a primary endpoint miss in its PreciSION CF Phase 2a trial and decided not to advance SION-719, causing its stock to fall over 91%. Shareholders who suffered losses are encouraged to contact the firm to learn about potentially recovering their investments.

SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Sionna Therapeutics, Inc. (NASDAQ: SION) for potential securities law violations. This investigation follows a significant drop in Sionna's share price after its SION-719 Phase 2a trial failed to meet its primary endpoint of sweat chloride reduction. SBS is inviting shareholders who suffered losses to participate in the investigation to discuss their rights.

Sionna Therapeutics (NASDAQ:SION) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded Sionna Therapeutics (NASDAQ:SION) to a "strong sell" rating. This comes amidst broader analyst sentiment leaning towards "hold," with the stock opening significantly below its 52-week high and reporting a quarterly loss that missed estimates. Insider selling has occurred, though some institutional investors increased their positions.

Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?

SION ALERT: Investigation Launched into Sionna Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

Robbins Geller Rudman & Dowd LLP has initiated an investigation into Sionna Therapeutics, Inc. (NASDAQ: SION) following a significant drop in its stock price. The investigation stems from the company's announcement on August 10, 2026, that its SION-719 Phase 2a trial failed to meet a key activity endpoint, causing Sionna Therapeutics stock to fall over 91%. Investors who suffered losses and have information are encouraged to contact the law firm for potential securities fraud litigation.

Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall

Sionna Therapeutics (NASDAQ:SION) Lowered to Hold Rating by JonesTrading

JonesTrading has downgraded Sionna Therapeutics (NASDAQ:SION) from a "strong buy" to a "hold" rating following the failure of its lead cystic fibrosis drug, SION-719, to meet its primary endpoint in a Phase 2 trial. This setback led to a significant stock price drop and numerous analyst downgrades, raising concerns about the company's future pipeline and financial needs. The stock currently holds a consensus "hold" rating with an average price target of $42.22, significantly higher than its current trading price of $5.10.

SION Q2 2026 Earnings: Narrower $0.66 Loss Drives 16.4% Jump in Shares - Financial Summary

Sionna Therapeutics, Inc. - Common Stock (SION) Stock Price, News, Quote & History

Sionna Therapeutics (SION) halted development of SION-719 after its Phase 2a study failed to meet the key activity endpoint for cystic fibrosis treatment, despite initially showing promise. The company is now focusing on the SION-451 combination path. This news follows previous reports on financial results, investor conferences, and insider stock transactions.

SION Stock Slides, Then Snaps Back As Traders Eye Volatility

Sionna Therapeutics Inc. (SION) stock experienced significant volatility, plunging from mid-$50s to around $5 before bouncing back intraday. Despite burning cash, the company boasts a strong balance sheet with $211.0M in cash and low debt, providing a substantial runway for its early-stage biotech strategy. Traders are closely monitoring SION for its price action, recognizing it as a volatile asset with clear technical levels and a substantial cash pile, making it a case study in market sentiment and technical trading.

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results—Johnson Fistel Investigates

Johnson Fistel, PLLP is investigating Sionna Therapeutics, Inc. (SION) for potential violations of federal securities laws after the company's shares plummeted following disappointing Phase 2a clinical trial results for SION-719. The trial failed to show meaningful improvement in cystic fibrosis, leading Sionna to halt further development of SION-719 as an add-on therapy. The investigation will examine whether investors suffered losses due to misleading statements or omissions regarding SION-719's potential.

Sionna Therapeutics stock falls 92% after SION-719 trial failure

Sionna Therapeutics experienced a 92% stock drop after its experimental cystic fibrosis drug, SION-719, failed to meet its key endpoint in a Phase 2a trial. The company will not advance SION-719 as an add-on therapy and is evaluating its SION-451 program, while considering workforce reductions to protect its cash runway. This outcome was unexpected by the company, which continues to analyze the data.